European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

9 EU fundings (€3,565,141): Early Interception of Inflammatory-mediated Type 2 Diabetes … BdlYear 2022 EU Research and Innovation programme "Horizon"

Text

Siren 434033619

01/06/2022 EU funding (€198,375): Building a European strategic Research and Innovation Area in Direct Synergy with EU and International Initiatives for Pandemic Preparedness
22/07/2022 EU funding (€217,500): A Coordination and Support Action to prepare UNCAN.eu platform
01/02/2022 EU funding (€297,918): Integrated Services for Infectious Disease Outbreak Research
05/08/2022 EU funding (€335,123): A clinical research network to improve the management of Monkeypox virus disease
01/07/2022 EU funding (€356,500): SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients
03/08/2022 EU funding (€396,975): Cardiac regeneration by mRNA-triggered proliferation of cardiomyocytes
01/12/2022 EU funding (€400,375): Early Interception of Inflammatory-mediated Type 2 Diabetes
18/11/2022 EU funding (€438,125): CArdiovascularREsolution of INflammation to promote HEALTH
28/11/2022 EU funding (€924,250): Improving treatment efficacy in hypertension by biomarker-guided personalised decision support

DATA SERVICES

Unlock the full potential of processed company data with our API or Quarterly Exports.

This filing was translated from to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Inserm Transfert SA, Paris, France.

Creative Commons License The visualizations for "9 EU fundings (€3,565,141): Early Interception of Inflammatory-mediated Type 2 Diabetes …" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.